Combined immunotherapy could help control melanoma that has spread to the brain

June 5, 2017
Combined immunotherapy could help control melanoma that has spread to the brain

A combination of two immunotherapy drugs is safe to give to patients with melanoma, a type of skin cancer, that has spread to the brain, and could help control the disease.

Melanomas that had spread to the brain responded to, or were kept stable, by the drugs ipilimumab (Yervoy) and nivolumab (Opdivo) in around half of patients, according to an early look at unpublished results from two clinical studies.

While patient numbers were small, the results could offer a new option if confirmed in future studies.

Dr Lynn Mara Schuchter, from the University of Pennsylvania in the US, said the findings 'could be practice changing'. But she added that patients now need to be followed up for longer.

Schuchter said that larger clinical trials would be needed to confirm the potential benefit for these patients, and to work out when is the best time to offer this treatment.

The findings were presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago in the US.

Little is known about how might be able to help control melanoma that has spread to the brain, a common complication in patients diagnosed with late stage disease.

Patients whose disease has spread to the brain have been ineligible for previous of immunotherapy for melanoma.

The phase 2 CheckMate 204 study , led by Dr Hussein Abdul-Hassan Tawbi from the University of Texas MD Anderson Cancer Center, and the phase 2 Anti-PD1 Brain Collaboration (ABC) trial , led by Professor Georgina Long from the University of Sydney, specifically recruited patients with melanoma that had spread to the brain. Most of these patients weren't experiencing symptoms as a result of the tumours in their brains.

Of the 75 patients treated on the CheckMate 204 study, 60 percent saw the disease in their brain respond to the combined treatment, or be kept stable by it, at the middle point of follow-up, which was 9.2 months.

16 patients (21 percent) saw the disease in their brain completely disappear following treatment.

Professor Peter Johnson, Cancer Research UK's chief clinician, said the results of the CheckMate 2014 study "suggest that a combination of the immunotherapy drugs nivolumab and ipilimumab is safe and effective against that's spread to the brain."

"Radiotherapy can have limited benefits, so these results are encouraging and may be another option for some patients in the future once larger trials are done," he added.

On the ABC trial, 42 percent of the 26 patients treated saw the disease in their brain respond to some degree to the combined immunotherapy drugs at the middle point of follow-up, which was 16.4 months after treatment. This increased to 50 percent when looking at 20 patients who had not previously been treated with a targeted cancer drug for melanoma, suggesting the immunotherapy combination may work better upfront, although these numbers are small.

4 patients (15 percent) saw the disease in their completely disappear following the combined immunotherapy treatment.

Six months after treatment, 67 percent of patients on the CheckMate 204 study hadn't seen their disease get worse, so-called progression free survival. On the ABC trial this was 46 percent.

Schuchter said that while these early results were 'fantastic', most patients on these studies did ultimately see their get worse. And across the different study groups between a quarter and half of patients who took part have died.

According to both lead researchers and Schuchter, the side effects experienced by on these studies were as expected for immunotherapy treatment of . But in some cases these can be serious, and must be carefully managed.

Explore further: Some head and neck cancer patients benefit from continued checkpoint inhibitor treatment

More information: Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204.

A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC).

Related Stories

Some head and neck cancer patients benefit from continued checkpoint inhibitor treatment

April 3, 2017
New research suggests that some patients with head and neck cancers can benefit by continuing treatment with an immunotherapy drug after their tumors show signs of enlargement according to investigators at Dana-Farber Cancer ...

New immunotherapy combination shows promise for patients with advanced melanoma

April 5, 2017
Treatment with a combination of ipilimumab (Yervoy) and Coxsackievirus A21 (CVA21; Cavatak) led to durable responses in a number of patients with advanced melanoma, including some whose melanoma had progressed despite prior ...

Adding the IDO-pathway inhibitor indoximod to pembrolizumab improved the melanoma response rate

April 5, 2017
Adding the investigational immunotherapy indoximod to the FDA-approved immunotherapy pembrolizumab (Keytruda) increased the proportion of patients with advanced melanoma who responded to treatment compared with previously ...

Two-drug immunotherapy deemed safe for lung cancer patients, study shows

June 2, 2016
Small cell lung cancer (SCLC) represents approximately 14 percent of all types of lung cancer. Many patients with SCLC respond to initial chemotherapy; however, they eventually relapse and develop progressive disease that ...

Surgery may be best for advanced melanoma

April 5, 2017
(HealthDay)—Surgery to remove melanoma—the deadliest form of skin cancer—can extend the lives of patients whose disease has spread to the abdomen area, new research suggests.

Immune and targeted therapies with radiation therapy improves outcomes for melanoma brain metastases patients

September 21, 2016
Brain metastases are one of the most common complications of advanced melanoma, requiring multidisciplinary management. Patients who are diagnosed with these metastases have an expected median survival of only 4 to 5 months. ...

Recommended for you

Study suggests colon cancer cells carry bacteria with them when they metastasize

November 24, 2017
(Medical Xpress)—A team of researchers working at Harvard University has found evidence that suggests a certain type of bacteria found in colon cancer tumors makes its way to tumors in other body parts by traveling with ...

Promising new treatment for rare pregnancy cancer leads to remission in patients

November 24, 2017
An immunotherapy drug can be used to cure women of a rare type of cancer arising from pregnancy when existing treatments have failed.

Researchers unravel novel mechanism by which tumors grow resistant to radiotherapy

November 23, 2017
A Ludwig Cancer Research study has uncovered a key mechanism by which tumors develop resistance to radiation therapy and shown how such resistance might be overcome with drugs that are currently under development. The discovery ...

African Americans face highest risk for multiple myeloma yet underrepresented in research

November 23, 2017
Though African-American men are three times more likely to be diagnosed with multiple myeloma, a type of blood cancer, most scientific research on the disease has been based on people of European descent, according to a study ...

Encouraging oxygen's assault on iron may offer new way to kill lung cancer cells

November 22, 2017
Blocking the action of a key protein frees oxygen to damage iron-dependent proteins in lung and breast cancer cells, slowing their growth and making them easier to kill. This is the implication of a study led by researchers ...

One in four U.S. seniors with cancer has had it before

November 22, 2017
(HealthDay)—For a quarter of American seniors, a cancer diagnosis signals the return of an old foe, new research shows.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.